Daily Cognitive Failures and Medication Adherence in Fibromyalgia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07904468, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Mardin Artuklu University
- Trial code
- NCT07904468
- Record updated
- 29 October 2026
- Original description
This study aims to investigate the relationship between everyday cognitive failures and medication adherence in adults with fibromyalgia.Read full original descriptionShow less
Daily Cognitive Failures and Medication Adherence in Fibromyalgia: A Cross-Sectional Study
This study aims to investigate the relationship between everyday cognitive failures and medication adherence in adults with fibromyalgia.
Fibromyalgia is a chronic condition associated with widespread pain, fatigue, and cognitive difficulties such as forgetfulness and problems with attention. These difficulties may affect patients' ability to take prescribed medications regularly, but their relationship with medication adherence remains unclear.
This single-center, observational, cross-sectional study will include 70 adults aged 18-65 years diagnosed with fibromyalgia who regularly take at least one medication for the condition.
Everyday cognitive failures will be assessed using the Cognitive Failures Questionnaire (CFQ), and medication adherence will be assessed using the five-item Medication Adherence Report Scale (MARS-5). Anxiety and depressive symptoms will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Information on pain severity, medications, and daily medication-taking frequency will also be collected.
The study will examine whether greater cognitive failures are associated with lower medication adherence and whether this relationship remains after accounting for anxiety, depressive symptoms, number of regularly used medications, and daily medication-taking frequency.
All assessments will be completed during a single visit lasting approximately 12-15 minutes. No experimental treatments, additional laboratory tests, or invasive procedures will be performed.
Inclusion: Adults aged 18-65 years; Diagnosis of fibromyalgia according to the 2016 American College of Rheumatology (ACR) criteria; Regular use of at least one medication for fibromyalgia; Willingness to participate in the study and provision of written informed consent.
Exclusion: Cognitive impairment severe enough to prevent reliable completion of the assessment questionnaires; Active psychotic disorder or severe psychiatric illness that significantly interferes with participation in the assessment; Pregnancy, postpartum period, or breastfeeding; Communication difficulties that prevent understanding or answering the study questionnaires.